ArticleProceedings of the National Academy of Sciences of the United States of America2006
Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 219 citations in OpenAlex.
- IgE Production Beyond Classical T-Cell Help.Immune network · 2026Review
- Natural killer T-cells in asthma pathogenesis and treatment: old problems and future perspectives.ERJ open research · 2025Review
- Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues.Cell reports · 2025Article
- Decoding innate lymphoid cells and innate-like lymphocytes in asthma: pathways to mechanisms and therapies.Journal of biomedical science · 2025Review
- Proteomic signatures of eosinophilic and neutrophilic asthma from serum and sputum.EBioMedicine · 2024Article
- Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.Frontiers in immunology · 2024Review
- Article
- Invariant natural killer T cells in lung diseases.Experimental & molecular medicine · 2023Review
- Microbial Dysbiosis Tunes the Immune Response Towards Allergic Disease Outcomes.Clinical reviews in allergy & immunology · 2023Review
- T-cell responses in asthma exacerbations.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022Review
- Microbiome profiling of uncinate tissue and nasal polyps in patients with chronic rhinosinusitis using swab and tissue biopsy.PloS one · 2021Article
- Invariant natural killer T cells balance B cell immunity.Immunological reviews · 2021Review
- Innate-like Lymphocytes and Innate Lymphoid Cells in Asthma.Clinical reviews in allergy & immunology · 2020Review
- Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response.Mucosal immunology · 2020Article
- Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells.Frontiers in immunology · 2020Review
- Similar immune mechanisms control experimental airway eosinophilia elicited by different allergens and treatment protocols.BMC immunology · 2019Article
- The role of invariant T cells in inflammation of the skin and airways.Seminars in immunopathology · 2019Review
- α-galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice.Journal of cellular and molecular medicine · 2019Article
- α-Lactosylceramide Protects Against iNKT-Mediated Murine Airway Hyperreactivity and Liver Injury Through Competitive Inhibition of Cd1d Binding.Frontiers in chemistry · 2019Article
- Innate T cells in the intensive care unit.Molecular immunology · 2019Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
Asthma is an inflammatory lung disease, in which conventional CD4+ T cells producing IL-4/IL-13 appear to play an obligatory pathogenic role. Here we show, in a mouse model of asthma, that activation of pulmonary IL-4/IL-13 producing invariant TCR+ CD1d-restricted natural killer T (NKT) cells is sufficient for the development of airway hyperreactivity (AHR), a cardinal feature of asthma, in the absence of conventional CD4+ T cells and adaptive immunity. Respiratory administration of glycolipid antigens that specifically activate NKT cells (alpha-GalactosylCeramide and a Sphingomonas bacterial glycolipid) rapidly induced AHR and inflammation typically associated with protein allergen administration. Naïve MHC class II-deficient mice, which lack conventional CD4+ T but have NKT cells, showed exaggerated baseline AHR and, when challenged with alpha-GalactosylCeramide, demonstrated even greater AHR. These studies demonstrate an expanded role for NKT cells, in which NKT cells not only produce cytokines that influence adaptive immunity but also function as critical effector cells that can induce AHR. These results suggest that NKT cells responding to glycolipid antigens, as well as conventional CD4+ T cells responding to peptide antigens, may be synergistic in the induction of AHR, although in some cases, each may independently induce AHR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.